GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Eliglustat+Immune checkpoint inhibitor+Regorafenib

"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."

DRUG

Eliglustat+Immune checkpoint inhibitor

"Eliglustat 84mg will be administered twice daily in the first 14 days and the following every other week.~Immune checkpoint inhibitor (physician decided) ."

DRUG

Regorafenib+Immune checkpoint inhibitor

"Immune checkpoint inhibitor (physician decided) .~Regorafenib orally 80mg daily .Dose escalation to 120mg daily was allowed if well tolerated."

Trial Locations (1)

Unknown

China, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT06558773 - GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. | Biotech Hunter | Biotech Hunter